Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab

NCT03149159 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped This study is withdrawn due to feasibility issues.

Conditions

Clear Cell Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma

Interventions

DRUG: Nivolumab
DRUG: Ipilimumab
RADIATION: Steriotactic radiation therapy

Sponsor

Medical University of South Carolina

Collaborators

[object Object]